Breaking Down Shandong Hualu-Hengsheng Chemical Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) represents resilience or risk for investors? Q3 2025 revenue slipped to 7.79 billion CNY (down 5.07% YoY) while TTM revenue as of Sept 30, 2025 was 32.60 billion CNY (‑1.50% YoY) despite a strong 2024 total of 34.23 billion CNY (up 25.55% from 2023); Q3 net profit attributable to shareholders was 805 million CNY (‑2.38% YoY) and nine‑month net profit fell to 2.37 billion CNY (‑22.14% YoY), with operating cash flow for Jan-Sep 2025 at 3.30 billion CNY (‑15.23% YoY) against total cash of 1.88 billion CNY and total debt of 10.45 billion CNY (debt‑to‑equity 30.78), while profitability and efficiency metrics show a profit margin of 9.83%, ROE of 10.74%, gross margin 17.01% and EBITDA margin 22.20%; valuation metrics include a trailing P/E of 13.22, forward P/E of 9.01, P/B of 1.48, market cap of 62.21 billion CNY (as of Dec 18, 2025) and a 52‑week range of 19.73-28.78 CNY with beta 1.14 - juxtaposed with growth initiatives that added 0.52 million tons/year of urea capacity and 0.2 million tons/year of adipic acid from new projects, plus ongoing upgrades and new‑materials expansions that could reshape future volumes and margins, making a deeper dive into the numbers essential for investors.

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) - Revenue Analysis

Key revenue trends and metrics for Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) through Q3 2025 and FY2024 are summarized below, highlighting recent growth, declines, efficiency, and market valuation.

• Q3 2025 revenue: 7.79 billion CNY (down 5.07% YoY).
• Trailing twelve months (TTM) revenue as of Sep 30, 2025: 32.60 billion CNY (down 1.50% YoY).
• Annual revenue 2024: 34.23 billion CNY (up 25.55% vs. 2023).
• Revenue per employee: 5.40 million CNY (total employees: 6,033).
• Price-to-sales (P/S) ratio: 1.91.
• Market capitalization: 62.21 billion CNY (as of Dec 18, 2025).

For additional background on corporate strategy, ownership and how the company generates revenue, see Shandong Hualu-Hengsheng Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money.

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) - Profitability Metrics

Key profitability indicators for Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) show moderation in earnings through Q3 2025 and weaker year-to-date performance versus 2024, while margin and return metrics for the trailing twelve months remain moderate for the chemical sector.

• Net profit attributable to shareholders (Q3 2025): 805 million CNY (-2.38% YoY).
• Net profit (9 months ended Sep 30, 2025): 2.37 billion CNY (-22.14% YoY).
• Basic and diluted EPS (Q3 2025): 0.38 CNY each (-2.06% YoY).

Implications for investors:

• Sequential softness in net profit and EPS suggests margin pressure or lower volumes in 2025 YTD despite healthy EBITDA and gross margins on a trailing twelve-month basis.
• ROE of 10.74% and ROA of 5.93% indicate mid-single-digit asset returns with modest shareholder-level returns relative to cost of equity benchmarks.
• Operating margin (15.13%) versus EBITDA margin (22.20%) points to non-operating or depreciation/amortization impacts-useful when modeling free cash flow and capital intensity.

For broader corporate context and stated strategic orientation, see: Mission Statement, Vision, & Core Values (2026) of Shandong Hualu-Hengsheng Chemical Co., Ltd.

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) - Debt vs. Equity Structure

Key balance-sheet indicators reveal how Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) funds operations and the cushion available to absorb shocks. The figures below are taken from the most recent quarter.

• Total debt: 10.45 billion CNY
• Total cash: 1.88 billion CNY
• Total cash per share: 0.89 CNY
• Book value per share: 14.609 CNY
• Current ratio: 1.406
• Total debt-to-equity ratio: 30.78

Interpretation highlights:

• The current ratio of 1.406 indicates the company maintains a modest short-term liquidity buffer - current assets cover current liabilities by about 40% beyond par.
• A debt-to-equity ratio of 30.78 reflects moderate leverage; debt is sizable in absolute terms (10.45 billion CNY) but not extreme relative to equity.
• Cash holdings of 1.88 billion CNY (0.89 CNY per share) provide a partial cushion against near-term obligations but cover only a fraction of total debt.
• Book value per share at 14.609 CNY offers a baseline for net asset claims against which market price and leverage should be compared.

For context on the company's strategic positioning and long-term objectives, see Mission Statement, Vision, & Core Values (2026) of Shandong Hualu-Hengsheng Chemical Co., Ltd.

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) Liquidity and Solvency

Key liquidity and solvency metrics for Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) through Q3/2025 and trailing twelve months provide a concise view of the company's short-term coverage and balance-sheet strength.

• Operating cash flow (first 9 months 2025): 3.30 billion CNY (-15.23% YoY)
• Levered free cash flow (TTM): 179.64 million CNY
• Total assets (end Q3 2025): 49.26 billion CNY (+5.57% vs prior year-end)
• Current ratio: 1.406 - indicates adequate short-term liquidity
• Quick ratio: not specified; typically lower than the current ratio due to inventory exclusion
• Cash flow from operations covers capital expenditures - supports solvency

• Implication for investors: a current ratio of 1.406 suggests adequate near-term liquidity, but the decline in operating cash flow (-15.23% YoY) and modest levered free cash flow (179.64 million CNY TTM) warrant monitoring of cash generation trends.
• Balance-sheet support: total assets grew to 49.26 billion CNY (+5.57% YoY), providing room for operational and strategic flexibility.
• Missing detail: the quick ratio is unspecified; investors should request or calculate it to assess liquidity excluding inventory.

See also: Mission Statement, Vision, & Core Values (2026) of Shandong Hualu-Hengsheng Chemical Co., Ltd.

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) - Valuation Analysis

• Trailing P/E: 13.22 - current market price relative to the last 12 months of earnings.
• Forward P/E: 9.01 - market-implied valuation based on projected earnings, materially below trailing P/E.
• Price-to-Book (P/B): 1.48 - market value compared to reported book equity per share.
• Enterprise Value / Revenue (EV/Rev): 1.66 - reflects how the market prices the company on a revenue basis including net debt.
• Enterprise Value / EBITDA (EV/EBITDA): 7.27 - indicates valuation relative to operating cash-profit before non-cash and financing items.
• Market Capitalization: 62.21 billion CNY (as of 2025-12-18).
• 52-week range: Low 19.73 CNY - High 28.78 CNY.
• Beta: 1.14 - modestly higher volatility than the broader market benchmark.

• Implication of the P/E spread: The forward P/E (9.01) being substantially lower than the trailing P/E (13.22) indicates either expected EPS growth, favorable one-time adjustments in trailing earnings, or analyst revisions improving near-term profitability assumptions.
• Relative valuation signals: A P/B of 1.48 positions the stock above book value but not at a large premium; EV/EBITDA of 7.27 implies a moderately attractive entry point versus many industrial/chemical peers that often trade higher in stronger markets.
• Market context: Market cap of 62.21 billion CNY and a beta of 1.14 suggest a sizeable company with moderate cyclicality-price sensitivity to commodity cycles, demand fluctuations, and macro conditions should be considered.
• Price momentum: The 52-week range (19.73-28.78 CNY) frames recent volatility and potential support/resistance zones for tactical entry or rebalancing decisions.

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) - Risk Factors

Investors should weigh a combination of operational, financial and market risks driven by recent performance trends and balance-sheet structure.

• Revenue contraction: Q3 2025 revenue fell by 5.07% year‑over‑year, signaling demand or pricing pressure in core product lines.
• Profitability deterioration: Net profit for the nine months ending September 30, 2025 declined by 22.14% YoY; reported profit and operating margins have trended downward across recent quarters.
• Cash-flow strain: Operating cash flow dropped 15.23% YoY in the first nine months of 2025, reducing internal funding capacity for capex and working capital.
• Leverage exposure: A total debt‑to‑equity ratio of 30.78 (expressed as a percentage) indicates meaningful leverage that amplifies earnings volatility and refinancing risk in tighter credit conditions.
• Share-price volatility: A 52‑week trading range of 19.73 CNY to 28.78 CNY reflects notable market sensitivity to news, results, and sector moves.

• Operational risk: input-cost volatility (raw materials, energy) can further compress margins if not passed through to customers.
• Market risk: reduced revenue and profit suggest exposure to weaker end‑market demand or intensified competition.
• Liquidity and refinancing risk: lower operating cash flow combined with elevated debt-to-equity raises the probability of funding stress under adverse macro conditions.
• Execution risk: recovery depends on effective cost controls, working-capital management, and successful commercial responses to price/mix pressures.
• Shareholder risk: price volatility increases the risk for short-term investors and complicates capital-raising at favorable terms.

For broader context on the company's origins, ownership and business model, see Shandong Hualu-Hengsheng Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Hualu-Hengsheng Chemical Co., Ltd. (600426.SS) - Growth Opportunities

• Completed capacity additions: melamine resin monomer/urea production (+0.52 million t/year) and adipic acid (+0.2 million t/year) now in operation, delivering near-term volume growth.
• Ongoing projects on schedule: amide raw material optimization upgrade, 0.2 million t/year dicarboxylic acid, and BDO-NMP integrated project - each aimed at higher-value product lines and integration efficiencies.
• Portfolio expansion into new materials and specialty chemicals to access differentiated markets (nylon 66 intermediates, specialty esters, polymer additives).
• Exploration of strategic partnerships and joint ventures to accelerate technology adoption, offload capex risk, and secure downstream offtake.

• Volume and mix: The +0.72 million t/year incremental capacity (urea + adipic acid) materially increases sales base and supports higher-margin downstream productization.
• Margin upside: Upgrades and integrated projects (BDO-NMP, adipic → nylon intermediates) are designed to shift sales mix toward higher-value, specialty applications.
• Execution risk vs. reward: On-schedule advancement of multiple projects reduces single-project concentration risk, but successful commercialization and market pricing will determine realized returns.
• Partnership optionality: Strategic JV opportunities can accelerate tech transfer and secure off-take agreements, de‑risking market entry for new materials.